Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;16(2):67-80.
doi: 10.1007/s10911-011-9215-3. Epub 2011 Apr 15.

Choreographing metastasis to the tune of LTBP

Affiliations

Choreographing metastasis to the tune of LTBP

Anupama Chandramouli et al. J Mammary Gland Biol Neoplasia. 2011 Jun.

Abstract

Latent Transforming Growth Factor beta (TGFβ) Binding Proteins (LTBPs) are chaperones and determinants of TGFβ isoform-specific secretion. They belong to the LTBP/Fibrillin family and form integral components of the fibronectin and microfibrillar extracellular matrix (ECM). LTBPs serve as master regulators of TGFβ bioavailability, functioning to incorporate and spatially pattern latent TGFβ at regular intervals within the ECM, and actively participate in integrin-mediated stretch activation of TGFβ in vivo. In so doing they create a highly patterned sensory system where local changes in ECM tension can be detected and transduced into focal signals. The physiological role of LTBPs in the mammary gland remains largely unstudied, however both loss and gain of LTBP expression is found in breast cancers and breast cancer cell lines. Importantly, elevated LTBP1 levels appear in two gene signatures predictive of enhanced metastatic behavior. LTBP may promote metastasis by providing the bridge between structural and signaling components of the epithelial to mesenchymal transition (EMT).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Assembly and function of latent-TGFβ. a The tripartite large latent complex (LLC) is formed early in the rough endoplasmic reticulum (RER), via disulphide bonding first between two TGFβ pro-protein monomers to form pro-TGFβ, and then between pro-TGFβ and the 8-cys domain of LTBP. In the Golgi, furin mediates the cleavage of pro-TGFβ into dimeric TGFβ and its propeptide, latency associated protein (LAP). These two homodimers associate non-covalently to form the small latent complex (SLC). LTBP acts as a chaperone, ensuring proper folding and disulphide bonding between LAP and TGFβ. LAP is also glycosylated in the Golgi at mannose-6-phosphate groups, which may be important in extracellular signaling. The mature LLC is then secreted. b The LLC positions itself within the extracellular matrix (ECM) first by LTBP binding through its N-terminus (N) to fibronectin and later through its C-terminus (C) binding to N-terminus of fibrillin in microfibrils. This maintains extracellular TGFβ in its latent state. c Latent TGFβ is activated via integrins in the stretch mechanism. Upon mechanical signal from the actin cytoskeleton, integrins bind to RGD sites on LAP. As LTBP maintains its hold on the ECM during this process, the two opposing forces allow a conformational change in LAP that releases TGFβ from the complex, activating it and allowing it to bind its receptor, TGF-βR
Figure 2
Figure 2
Members of the LTBP/Fibrillin family. Four LTBPs and three fibrillins are known. LTBPs have internal promoter initiation sites (black arrows) and undergo alternative splicing giving rise to splice variants (pink dotted lines). LTBP and fibrillin contain 8-Cys repeats (red globules) and the EGF-like repeats. EGF-like repeats can either bind to calcium (grey rods), giving the protein its rigidity, or can remain unbound (green rods). Hybrid domains (brown globules) have combined features of 8-Cys and EGF-like repeats. The small latent TGFβ-LAP complex (SLC) binds to a specific 8-Cys domain found only in LTBP 1, 3 and 4, adjacent to the fibrillin binding C-terminal region. LTBPs also have a central hinge region for additional flexibility. The hinge and the hybrid domains form a major site for ECM attachment and play a role in the stretch response when interacting with integrins. Fibrillins contain a unique C-terminal conserved region (blue rods and purple octagons). RGD domains (yellow arrowheads) present in LAP and in fibrillins are functional and bind to integrins. Although present in LTBP their integrin binding function has not been established
Figure 3
Figure 3
Expression pattern of LTBP-1 during mammary development, using LTBP1L-LacZ mouse model. a LTBP1L-LacZ (blue) is expressed in the mammary mesenchyme surrounding the embryonic (E) E12.5 (left) mammary bud, and persists at this site under the developing nipple E17.5. LTBP1L-LacZ becomes additionally expressed within the luminal epithelium of the rudimentary sprout as the lumen first forms. b During puberty, LTBP1L-LacZ is expressed in quiescent ductal luminal cells but not in the terminal end buds. c During pregnancy, LTBP1L-LacZ expression is high in the luminal cells of ducts and side branches, but is absent from secretory structures such as alveoli. d LTBP1L-LacZ is not expressed during lactation, but is seen in a subset of cells during involution
Figure 4
Figure 4
Model for potential LTBP interactions with the ECM in mammary gland. Integrins are multifunctional proteins, which can specify cellular responses in multiple ways. a Cells use integrin α5β1 (brown) to bind directly to fibronectin (FN) in the ECM. Mammary cells express αVβ5 (yellow) and αVβ3 (orange), which in other cells have been shown to bind to the RGD domains (yellow arrowheads) of LAP. b αVβ5 (yellow) and αVβ3 (orange) interactions can also form between the cell surface and fibrillins. The integrin-LLC association with fibronectin and fibrillins provide extra footholds between the cell and the matrix. Different matrix molecules assemble distinct complements and arrangements of integrins. In the case of fibronectin it is hypothesized that stretch mediated integrin activation of TGFβ will stimulate the EMT transcriptional program to reinforce migratory behavior

Similar articles

  • TGFβ biology in breast: 15 years on.
    Barcellos-Hoff MH. Barcellos-Hoff MH. J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):65-6. doi: 10.1007/s10911-011-9220-6. J Mammary Gland Biol Neoplasia. 2011. PMID: 21534008 No abstract available.
  • LTBPs in biology and medicine: LTBP diseases.
    Rifkin DB, Rifkin WJ, Zilberberg L. Rifkin DB, et al. Matrix Biol. 2018 Oct;71-72:90-99. doi: 10.1016/j.matbio.2017.11.014. Epub 2017 Dec 5. Matrix Biol. 2018. PMID: 29217273 Free PMC article. Review.
  • Noncanonical TGF-β signaling during mammary tumorigenesis.
    Parvani JG, Taylor MA, Schiemann WP. Parvani JG, et al. J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):127-46. doi: 10.1007/s10911-011-9207-3. Epub 2011 Mar 31. J Mammary Gland Biol Neoplasia. 2011. PMID: 21448580 Free PMC article. Review.
  • Latent TGF-β-binding proteins.
    Robertson IB, Horiguchi M, Zilberberg L, Dabovic B, Hadjiolova K, Rifkin DB. Robertson IB, et al. Matrix Biol. 2015 Sep;47:44-53. doi: 10.1016/j.matbio.2015.05.005. Epub 2015 May 8. Matrix Biol. 2015. PMID: 25960419 Free PMC article. Review.
  • Latent TGFβ complexes are transglutaminase cross-linked to fibrillin to facilitate TGFβ activation.
    Lockhart-Cairns MP, Cain SA, Dajani R, Steer R, Thomson J, Alanazi YF, Kielty CM, Baldock C. Lockhart-Cairns MP, et al. Matrix Biol. 2022 Mar;107:24-39. doi: 10.1016/j.matbio.2022.01.005. Epub 2022 Feb 3. Matrix Biol. 2022. PMID: 35122964 Free PMC article.

Cited by

References

    1. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ. 1998;9(3):229–38. - PubMed
    1. Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci. 2004;41(3):233–64. - PubMed
    1. Ewan KB, Shyamala G, Ravani SA, et al. Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am J Pathol. 2002;160(6):2081–93. - PMC - PubMed
    1. Robinson SD, Silberstein GB, Roberts AB, Flanders KC, Daniel CW. Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development. 1991;113(3):867–78. - PubMed
    1. Joseph H, Gorska AE, Sohn P, Moses HL, Serra R. Over-expression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell. 1999;10(4):1221–34. - PMC - PubMed

Publication types

MeSH terms

Substances